Cancer Family
Malignant Bone Marrow Neoplasm
CI-CAN-00000226Explore in graph →
1,035 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000226Explore in graph →
Clinical trials
4,612 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (801)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02979366 | Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome | completed | Phase 1 | 38 | Institut de Recherches Internationales ServierOTHER | 4 | May 18, 2022 | clinicaltrials |
| NCT03429387 | PET/CT and Bacterial/Fungal PCR in High Risk Febrile Neutropenia(PIPPIN) | completed | N/A | 147 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 17, 2022 |
| clinicaltrials |
| NCT02953704 | Myelofibrosis and Essential Thrombocythemia Observational Study (MOST) | completed | — | 1,469 | Incyte CorporationINDUSTRY | 2 | May 13, 2022 | clinicaltrials |
| NCT02200978 | A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia | completed | Phase 4 | 176 | South China Children's Leukemia GroupOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT03075826 | A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms | completed | Phase 2 | 22 | Weill Medical College of Cornell UniversityOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT00450450 | Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases | completed | Phase 3 | 27 | Children's Oncology GroupNETWORK | 1 | Apr 28, 2022 | clinicaltrials |
| NCT01387763 | A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms(DALIAH) | completed | Phase 3 | 202 | Thomas Stauffer LarsenOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT03449745 | Immune Checkpoint Receptors in AML-Leukemic Initiating Cells(ICAML-LIC) | completed | — | 199 | University Hospital, BordeauxOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT03563560 | A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia(AML) | completed | Phase 1 | 10 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT03678454 | Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium | completed | — | 80 | Incyte Biosciences BeneluxINDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT03787498 | A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | completed | Phase 1 | 22 | Opna Bio LLCINDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT02566395 | Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies | completed | Phase 3 | 10 | Northwell HealthOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT00900809 | QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia | completed | Phase 1 | 7 | ImmunityBio, Inc.INDUSTRY | 1 | Apr 5, 2022 | clinicaltrials |
| NCT04014764 | Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy((ANSWer)) | completed | — | 119 | Notable LabsINDUSTRY | 3 | Apr 5, 2022 | clinicaltrials |
| NCT01411267 | AC220 for Children With Relapsed/Refractory ALL or AML | completed | Phase 1 | 24 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT02353728 | Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy | completed | Phase 2 | 16 | Weill Medical College of Cornell UniversityOTHER | 1 | Mar 25, 2022 | clinicaltrials |
| NCT00531232 | A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS) | completed | Phase 2 | 38 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 24, 2022 | clinicaltrials |
| NCT01683123 | Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT(BUFLU) | completed | — | 143 | Grupo Espanol de trasplantes hematopoyeticos y terapia celularOTHER | 0 | Mar 17, 2022 | clinicaltrials |
| NCT03985007 | CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 40 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 17, 2022 | clinicaltrials |
| NCT01433965 | Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | completed | Phase 1 | 16 | University of California, DavisOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT01423851 | Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF | completed | Phase 1 / Phase 2 | 77 | NS Pharma, Inc.INDUSTRY | 1 | Mar 9, 2022 | clinicaltrials |
| NCT03719183 | Comparison of Diagnostic Yield Among M-FISH, FISH Probe Panel and Conventional Cytogenetic Analysis in AML | completed | — | 120 | Assiut UniversityOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT02730312 | PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies | completed | Phase 1 | 120 | Xencor, Inc.INDUSTRY | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03012672 | Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm | completed | Phase 2 | 50 | University of WashingtonOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT04327037 | Safety of Expanded Haploidentical Natural Killer Cells for Leukemia | completed | Phase 1 | 10 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT01810705 | GRASPA Treatment for Patients With Acute Myeloblastic Leukemia(ENFORCE) | completed | Phase 2 | 123 | ERYtech PharmaINDUSTRY | 1 | Feb 21, 2022 | clinicaltrials |
| NCT00352365 | Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2022 | clinicaltrials |
| NCT00426205 | GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies | completed | N/A | 28 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 11, 2022 | clinicaltrials |
| NCT04039100 | Family Caregiver Ambassador Support for Family Caregivers of Patients With Hematological Disease | completed | N/A | 43 | Rigshospitalet, DenmarkOTHER | 1 | Feb 8, 2022 | clinicaltrials |
| NCT03441555 | A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia | completed | Phase 1 | 36 | AbbVieINDUSTRY | 3 | Feb 1, 2022 | clinicaltrials |
| NCT00369317 | Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes | completed | Phase 3 | 205 | Children's Oncology GroupNETWORK | 4 | Jan 28, 2022 | clinicaltrials |
| NCT01578954 | Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction | completed | Phase 1 | 20 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT01841333 | PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant | completed | Phase 2 | 31 | University of Colorado, DenverOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT03072043 | Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms | completed | Phase 1 / Phase 2 | 55 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 24, 2022 | clinicaltrials |
| NCT00481052 | Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase(CML0307) | completed | Phase 2 | 74 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 18, 2022 | clinicaltrials |
| NCT04158726 | Integrating Geriatric Assessment for Older Patients Diagnosed With Acute Myelogenous Leukemia | completed | N/A | 47 | Carevive Systems, Inc.INDUSTRY | 1 | Jan 18, 2022 | clinicaltrials |
| NCT02914977 | Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia | completed | Phase 1 | 18 | Tara LinOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT04695431 | Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM | completed | — | 317 | Blueprint Medicines CorporationINDUSTRY | 5 | Jan 10, 2022 | clinicaltrials |
| NCT02083250 | Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 6, 2022 | clinicaltrials |
| NCT01981850 | A Phase 2 Study of RO7490677 In Participants With Myelofibrosis | completed | Phase 2 | 125 | Hoffmann-La RocheINDUSTRY | 8 | Jan 5, 2022 | clinicaltrials |
| NCT00038675 | Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate | completed | N/A | 125 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT02986620 | Italian Registry on the Prevalence of IDH1/IDH2 Mutations in Patients With Acute Myeloid Leukemia | completed | — | 388 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT00462943 | Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML | completed | Phase 2 | 100 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 10 | Dec 28, 2021 | clinicaltrials |
| NCT03459859 | Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS | completed | Phase 1 | 12 | Justin Watts, MDOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT03824080 | Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes | completed | Phase 2 | 45 | GWT-TUD GmbHOTHER | 3 | Dec 21, 2021 | clinicaltrials |
| NCT00380653 | Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes | completed | Phase 1 | 47 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 13, 2021 | clinicaltrials |
| NCT05149339 | Vitamin D Effect on A Disintegrin-like And Metalloprotease Thrombospondin1 Motif 13& Interleukin 6 in Leukemia | completed | Phase 1 / Phase 2 | 38 | Zagazig UniversityOTHER_GOV | 1 | Dec 8, 2021 | clinicaltrials |
| NCT01597778 | Double Cord Versus Haploidentical (BMT CTN 1101) | completed | Phase 3 | 368 | Medical College of WisconsinOTHER | 1 | Dec 1, 2021 | clinicaltrials |
| NCT01404949 | Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy | completed | Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Nov 30, 2021 | clinicaltrials |
Data updated 24 days agoSource updated May 18, 2022source: clinicaltrials